From Resistance to Rescue: Allele-Informed Salvage Therapy Following Daraxonrasib Resitance in Pancreatic Cancer (AACRPanCa 2026) - Oct 15, 2026 - Abstract #B060; "The shift toward EGFR/wild-type RAS dependence in the G12R setting conferred sensitivity to trametinib. KRAS allele identity dictates the topology of the adaptive resistance network following RAS(ON) inhibitor therapy, generating allele-specific and therapeutically actionable vulnerabilities. These data establish a mechanistic and translational framework, validated with a rapid patient-derived toroid platform, for rational, mechanism-informed salvage therapy selection in patients who progress on RAS inhibitors.Citation Format:Thomas McFall, Daniel Dorbin, Juliannie Herrera, Raven Davidson, Douglas B. Evans, Susan Tsai, K. Nikki, Y. David Seo, Razelle Kurzrock, G. Aaron Hobbs, Mandana Kamgar. From Resistance to Rescue: Allele-Informed Salvage Therapy Following Daraxonrasib Resitance in Pancreatic Cancer [abstract]."
Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • EGFR • KRAS
|
|
Thomas McFall; Daniel Dorbin; Juliannie Herrera; Raven Davidson; Douglas B. Evans; Susan Tsai; K. Nikki; Y. David Seo; Razelle Kurzrock; G. Aaron Hobbs; Mandana Kamgar
|